SCHEMBL3387653

SCHEMBL3387653

CCCC1(c2ccccc2)CC(=O)N(c2cccc(Cc3n[nH]c(=O)c4ccccc34)c2)C1=O

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 20/20 0.57
AR P10275 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13006821 0.83 PARP1 (0.61) PARP1AR
SCHEMBL3389570 0.83 PARP1 (0.71) PARP1AR
SCHEMBL3388026 0.79 PARP1 (0.64) PARP1AR
SCHEMBL3387621 0.77 PARP1 (0.76) PARP1AR
SCHEMBL3385186 0.74 PARP1 (0.80) PARP1AR
SCHEMBL3389677 0.74 PARP1 (1.00) PARP1AR
SCHEMBL3390432 0.73 PARP1 (0.66) PARP1AR
SCHEMBL3385194 0.73 PARP1 (1.00) PARP1AR
SCHEMBL24389992 0.73 PARP1 (0.62) PARP1AR
SCHEMBL29565612 0.73 PARP1 (0.62) PARP1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501822-B1 PHTHALAZINONE DERIVATIVES KUDOS PHARM LTD (GB) 2010-12-15 EP disclosed
US-7196085-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2007-03-27 US disclosed
US-7196085-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2007-03-27 US disclosed
EP-1501822-A1 PHTHALAZINONE DERIVATIVES Kudos Pharmaceuticals Limited (GB) 2005-02-02 EP disclosed
US-20040023968-A1 Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2004-02-05 US disclosed
WO-2003093261-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023968-A1 Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors PARP1, PARP2, PARP15 PARP1 1/4885AR 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.